科学图书馆
-
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionSD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray, -
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 InhibitorsS Verma, S Rawat, KL Ho et al.
-
SPECT and PET in ischemic heart failureAngelidis G, Giamouzis G, Karagiannis G et al.
-
Dilated cardiomyopathy: so many cardiomyopathies!G Sinagra, PM Elliott, M Merlo et al.
-
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREDewan P, Jackson A, Jhund PS et al.
-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators.
-
Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failureHC Chang, CJ Huang, HM Cheng et al.
-
Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry studyA Ghimire, N Fine, FA McAlister et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
